Corteva Cuts FY26 Outlook as Brazil Slump Drives Q3 Sales Down 9%
CTVA sits 28% above its 52-week low of $9.536.
Summary
Corteva posted a Q3 loss of $54 million, or $0.08 a share, as net sales fell 9% to $1.59 billion, short of the IBES estimate of USD 1,764 million, and operating EBITDA dropped 17% to $222 million. The damage is concentrated in Latin America, where organic sales fell 31% on a 24% volume decline tied to elevated channel inventory, farmer liquidity constraints and high interest rates in Brazil; North America grew 7% and EMEA 14% organically. Management cut full-year 2026 guidance to adjusted operating EBITDA of $1.1-$1.125 billion and operating EPS of $0.76-$0.80, citing a Brazil crop protection market significantly softer than previously anticipated. This lands on top of an already rough stretch: the Vylor seed spin-off closed October 1, a 15-state fraud lawsuit was filed against Corteva and Vylor the same day, and an October 13 8-K disclosed a restraining order blocking dividends and buybacks. The board did authorize a first post-spin common dividend. The earnings call is tomorrow, November 12, at 10:30 a.m. ET.
Updates
· SEC 8-K — Corteva's 8-K includes unaudited pro forma combined financials for New Corteva as of Sept. 30, 2026, giving effect to the spin-off and related capital structure transactions.
At the time of this announcement, CTVA was trading at $12.19 on NYSE in the Life Sciences sector, with a market capitalization of approximately $8.1B. The 52-week trading range was $9.54 to $14.62. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.